The researchers analyzed the expression of specific receptors and ectonucleotidases of the purinergic system (CD39, CD73, P2X4, and P2X7) in tumor cells and surrounding tissues from 139 patients with NSCLC. This evidence concerns the gene P2RX7 and neoplasm.